Cargando…

Airway allergen exposure stimulates bone marrow eosinophilia partly via IL-9

BACKGROUND: Interleukin (IL)-9 is a Th2-derived cytokine with pleiotropic biological effects, which recently has been proposed as a candidate gene for asthma and allergy. We aimed to evaluate the therapeutic effect of a neutralizing anti-IL-9 antibody in a mouse model of airway eosinophilic inflamma...

Descripción completa

Detalles Bibliográficos
Autores principales: Sitkauskiene, Brigita, Rådinger, Madeleine, Bossios, Apostolos, Johansson, Anna-Karin, Sakalauskas, Raimundas, Lötvall, Jan
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2005
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1090617/
https://www.ncbi.nlm.nih.gov/pubmed/15823208
http://dx.doi.org/10.1186/1465-9921-6-33
_version_ 1782123904322502656
author Sitkauskiene, Brigita
Rådinger, Madeleine
Bossios, Apostolos
Johansson, Anna-Karin
Sakalauskas, Raimundas
Lötvall, Jan
author_facet Sitkauskiene, Brigita
Rådinger, Madeleine
Bossios, Apostolos
Johansson, Anna-Karin
Sakalauskas, Raimundas
Lötvall, Jan
author_sort Sitkauskiene, Brigita
collection PubMed
description BACKGROUND: Interleukin (IL)-9 is a Th2-derived cytokine with pleiotropic biological effects, which recently has been proposed as a candidate gene for asthma and allergy. We aimed to evaluate the therapeutic effect of a neutralizing anti-IL-9 antibody in a mouse model of airway eosinophilic inflammation and compared any such effect with anti-IL-5 treatment. METHODS: OVA-sensitized Balb/c mice were intraperitoneally pretreated with a single dose (100 μg) of an anti-mouse IL-9 monoclonal antibody (clone D9302C12) or its vehicle. A third group was given 50 μg of a monoclonal anti-mouse IL-5 antibody (TRFK-5) or its vehicle. Animals were subsequently exposed to OVA on five days via airways. Newly produced eosinophils were labelled using 5-bromo-2'-deoxyuridine (BrdU). BrdU(+ )eosinophils and CD34(+ )cell numbers were examined by immunocytochemistry. After culture and stimulation with OVA or PMA+IC, intracellular staining of IL-9 in bone marrow cells from OVA-exposed animals was measured by Flow Cytometry. The Mann-Whitney U-test was used to determine significant differences between groups. RESULTS: Anti-IL-9 significantly reduced bone marrow eosinophilia, primarily by decrease of newly produced (BrdU(+)) and mature eosinophils. Anti-IL-9 treatment also reduced blood neutrophil counts, but did not affect BAL neutrophils. Anti-IL-5 was able to reduce eosinophil numbers in all tissue compartments, as well as BrdU(+ )eosinophils and CD34(+ )progenitor cells, and in all instances to a greater extent than anti-IL-9. Also, FACS analysis showed that IL-9 is over-expressed in bone marrow CD4(+ )cells after allergen exposure. CONCLUSIONS: Our data shows that a single dose of a neutralizing IL-9 antibody is not sufficient to reduce allergen-induced influx of newly produced cells from bone marrow to airways. However, in response to allergen, bone marrow cells over-express IL-9. This data suggest that IL-9 may participate in the regulation of granulocytopoiesis in allergic inflammation.
format Text
id pubmed-1090617
institution National Center for Biotechnology Information
language English
publishDate 2005
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-10906172005-05-07 Airway allergen exposure stimulates bone marrow eosinophilia partly via IL-9 Sitkauskiene, Brigita Rådinger, Madeleine Bossios, Apostolos Johansson, Anna-Karin Sakalauskas, Raimundas Lötvall, Jan Respir Res Research BACKGROUND: Interleukin (IL)-9 is a Th2-derived cytokine with pleiotropic biological effects, which recently has been proposed as a candidate gene for asthma and allergy. We aimed to evaluate the therapeutic effect of a neutralizing anti-IL-9 antibody in a mouse model of airway eosinophilic inflammation and compared any such effect with anti-IL-5 treatment. METHODS: OVA-sensitized Balb/c mice were intraperitoneally pretreated with a single dose (100 μg) of an anti-mouse IL-9 monoclonal antibody (clone D9302C12) or its vehicle. A third group was given 50 μg of a monoclonal anti-mouse IL-5 antibody (TRFK-5) or its vehicle. Animals were subsequently exposed to OVA on five days via airways. Newly produced eosinophils were labelled using 5-bromo-2'-deoxyuridine (BrdU). BrdU(+ )eosinophils and CD34(+ )cell numbers were examined by immunocytochemistry. After culture and stimulation with OVA or PMA+IC, intracellular staining of IL-9 in bone marrow cells from OVA-exposed animals was measured by Flow Cytometry. The Mann-Whitney U-test was used to determine significant differences between groups. RESULTS: Anti-IL-9 significantly reduced bone marrow eosinophilia, primarily by decrease of newly produced (BrdU(+)) and mature eosinophils. Anti-IL-9 treatment also reduced blood neutrophil counts, but did not affect BAL neutrophils. Anti-IL-5 was able to reduce eosinophil numbers in all tissue compartments, as well as BrdU(+ )eosinophils and CD34(+ )progenitor cells, and in all instances to a greater extent than anti-IL-9. Also, FACS analysis showed that IL-9 is over-expressed in bone marrow CD4(+ )cells after allergen exposure. CONCLUSIONS: Our data shows that a single dose of a neutralizing IL-9 antibody is not sufficient to reduce allergen-induced influx of newly produced cells from bone marrow to airways. However, in response to allergen, bone marrow cells over-express IL-9. This data suggest that IL-9 may participate in the regulation of granulocytopoiesis in allergic inflammation. BioMed Central 2005 2005-04-11 /pmc/articles/PMC1090617/ /pubmed/15823208 http://dx.doi.org/10.1186/1465-9921-6-33 Text en Copyright © 2005 Sitkauskiene et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Sitkauskiene, Brigita
Rådinger, Madeleine
Bossios, Apostolos
Johansson, Anna-Karin
Sakalauskas, Raimundas
Lötvall, Jan
Airway allergen exposure stimulates bone marrow eosinophilia partly via IL-9
title Airway allergen exposure stimulates bone marrow eosinophilia partly via IL-9
title_full Airway allergen exposure stimulates bone marrow eosinophilia partly via IL-9
title_fullStr Airway allergen exposure stimulates bone marrow eosinophilia partly via IL-9
title_full_unstemmed Airway allergen exposure stimulates bone marrow eosinophilia partly via IL-9
title_short Airway allergen exposure stimulates bone marrow eosinophilia partly via IL-9
title_sort airway allergen exposure stimulates bone marrow eosinophilia partly via il-9
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1090617/
https://www.ncbi.nlm.nih.gov/pubmed/15823208
http://dx.doi.org/10.1186/1465-9921-6-33
work_keys_str_mv AT sitkauskienebrigita airwayallergenexposurestimulatesbonemarroweosinophiliapartlyviail9
AT radingermadeleine airwayallergenexposurestimulatesbonemarroweosinophiliapartlyviail9
AT bossiosapostolos airwayallergenexposurestimulatesbonemarroweosinophiliapartlyviail9
AT johanssonannakarin airwayallergenexposurestimulatesbonemarroweosinophiliapartlyviail9
AT sakalauskasraimundas airwayallergenexposurestimulatesbonemarroweosinophiliapartlyviail9
AT lotvalljan airwayallergenexposurestimulatesbonemarroweosinophiliapartlyviail9